Year All2024202320222021202020192018201720162014201320112010 October 8, 2024 Rhythm Pharmaceuticals Announces New Employment Inducement Grants September 16, 2024 Rhythm Pharmaceuticals Announces New Employment Inducement Grants August 26, 2024 Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old August 26, 2024 Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September August 13, 2024 Rhythm Pharmaceuticals Announces New Employment Inducement Grants August 6, 2024 Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update July 31, 2024 Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old July 23, 2024 Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity July 23, 2024 Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024 July 11, 2024 Rhythm Pharmaceuticals Announces New Employment Inducement Grants
August 26, 2024 Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old
August 6, 2024 Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update
July 31, 2024 Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old
July 23, 2024 Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity
July 23, 2024 Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
